Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients

Journal of Hypertension

Volumn 28, Issue 10, 2010, Pages 2120-2126

  Stehr, Carlos B ^a   Mellado, Rosemarie ^b   Ocaranza, Maria P ^a   Carvajal, Cristian A ^a   Mosso, Lorena ^a   Becerra, Elia ^a   Solis, Margarita ^a   García, Lorena ^a   Lavandero, Sergio ^a   Jalil, Jorge ^a   Fardella, Carlos E ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

aldosterone; endothelial inflammation; myocardial fibrosis; oxidative stress; primary aldosteronism

Indexed keywords

ALDOSTERONE; AMINO TERMINAL TELOPEPTIDE; C REACTIVE PROTEIN; DEXAMETHASONE; GELATINASE B; MALONALDEHYDE; MINERALOCORTICOID RECEPTOR; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SPIRONOLACTONE; XANTHINE OXIDASE;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE MARKER; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL;

EID: 77957262136     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833d0177     Document Type: Article

References (40)

1. Takeda R, Hatakeyama H, Takeda Y, Iki K, Miyamori I, Sheng WP, et al. Aldosterone biosynthesis and action in vascular cells. Steroids 1995; 60:120-124.
2. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary hyperaldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248.
3. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 6:865-879.
4. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40:23-27.
5. Muiesan ML, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52:529-534.
6. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50:911-918.
7. Ridker P, Hennekens CH, Buring J, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843. (Pubitemid 30165206)
8. Sabatine M, Morrow D, Jablonski K, Domanski M, Hsia J, Gersh BJ, et al. Prognostic significance of the centers for disease control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115:1528-1536.
9. Schonbeck U, Mach F, Sukhova G, Murphy C, Bonnefoy JY, Fabunmi R, et al. Regulation of matrix met al.loproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997; 81:448-454.
10. Packard R, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54:24-38.
11. Blankenberg S, Rupprecht H, PoirierO, Bickel C, Smieja M, HafnerG, et al. Plasma concentrations and genetic variation of matrix met al.loproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107:1579-1585.
12. Irita J, Okura T, Manabe S, Kurata M, Miyoshi K, Watanabe S, et al. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens 2006; 19:293-297.
13. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358:21482159.
14. Brown N. Aldosterone and vascular inflammation. Hypertension 2008; 51:161-167.
15. Landmesser U, Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007; 22:316-320.
16. Glowinska-Olszewska B, Urban M. Elevated matrix met al.loproteinase 9 and tissue inhibitors of met al.loproteinase 1 in obese children and adolescents. Metabolism 2007; 56:799-805.
17. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992; 120:893-901.
18. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93:2578-2583.
19. Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild to moderate arterial hypertension. Am J Hypertens 2003; 16:439-444.
20. Heeneman S, Cleutjens JP, Faber BC, Creemers EE, van Suylen RJ, Lutgens E, et al. The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis. J Pathol 2003; 200: 516-525.
21. Cicoira M, Rossi A, Bonapace S, Zanolla L, Golia G, Franceschini L, et al. Independent and additional prognostic value of amino-terminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004; 10:403-411.
22. Tsuda T, Evangelisti L, Markova D, Ma X, Chu M. Postischemic myocardial fibrosis occurs independent of hemodynamics changes. Cardiovas Res 2003; 59:926-933.
23. Mosso L, Carvajal C, Gonzalez A, Avila F, Montero J, Huete A, et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42:161-165.
24. Mosso L, Carvajal C, Maiz A, Ortiz E, Castillo C, Artigas R, et al. A possible association between primary aldosteronism and a lower (-cell function. J Hypertens 2007; 25:2125-2130.
25. Kreft C, Menard J, Corvol P. Value of renin measurement, saralasin test, andacelretolol treatment in hypertension. Kidney Int 1979; 15:176183.
26. Castro P, Greig D, Perez O, Moraga F, Chiong M, Diaz-Araya G, et al. Relation between oxidative stress, catecholamines, and impaired chronotropic response to exercise in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003; 92:215-218.
27. Prajda N, Weber G. Malignant transformation-linked imbalance: decreased xanthine oxidase activity in hepatomas. FEBS Lett 1975; 59:245-249.
28. Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H, et al. Correlation of oxidative stress with activity of matrix met al.loproteinase in patients with coronary artery disease: possible role for left ventricular remodelling. Eur Heart J 2003; 24:2180-2185.
29. Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J 2007; 54:359-370.
30. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase role in cardiovascular biology and disease. Circ Res 2000; 86:494-501.
31. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001; 38:1107-1111.
32. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007; 116:1234-1241.
33. Godfrey V, Farquharson C, Macdonald J, Yee K, Struthers A. Effect of spironolactone on C-reactive protein levels in patients with heart disease [letter]. Int J Cardiol 2003; 117:282-284.
34. Gonzalez A, Lopez B, Ravassa J, Beaumont J, Arias T, Hermida N, et al. Biochemical markers of myocardial remodelling in hypertensive heart disease. Cardiovasc Res 2009; 81:509-518.
35. Ocaranza MP, Jalil JE. Mitogen-activated protein kinases as biomarkers of hypertension or cardiac pressure overload. Hypertension 2010; 55:23-25.
36. Swynghedauw B. Molecular mechanism of myocardial remodeling. Physiol Rev 1999; 79:215-262.
37. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitations of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102:2700-2706.
38. Lopez B, Gonzalez A, Querejeta R, Diez J. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005; 23:1445-1451.
39. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010; 121:1645-1654.
40. Carvajal C, Herrada A, Castillo C, Contreras FJ, StehrCB, Mosso LM, et al. Primary aldosteronism can alter peripheral levels of TGF-b and TNF-a. J Endocrinol Invest 2009; 32:759-765.